Geron to Present at 2019 Cantor Global Healthcare Conference
26 sept. 2019 16h18 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a...
Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock
23 sept. 2019 08h52 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit
16 sept. 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
26 août 2019 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results
14 août 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics
12 août 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel...
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
08 août 2019 08h08 HE
|
Geron Corporation
MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate...
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events
01 août 2019 16h05 HE
|
Geron Corporation
MENLO PARK, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the second quarter ended June 30, 2019, and recent events. The Company...
Geron to Announce Second Quarter Financial Results on August 1, 2019
25 juil. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2019 financial results after the market closes on...
Geron Enhances Oncology Expertise to Advance Corporate Objectives
18 juil. 2019 16h15 HE
|
Geron Corporation
MENLO PARK, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky...